SCHEDULE 13G/A: Prudential Financial Updates Passive Stake in Phathom Pharmaceuticals, Inc.

Prudential Financial, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2,630 common shares, representing 0.0% of Phathom Pharmaceuticals, Inc.

Summary

• Prudential Financial, Inc. filed an Amendment No. 2 to Schedule 13G concerning its beneficial ownership in Phathom Pharmaceuticals, Inc.
• As of May 31, 2025, Prudential Financial, Inc. beneficially owns an aggregate of 2,630 common shares of Phathom Pharmaceuticals, Inc.
• This ownership represents 0.0% of the total outstanding common stock of Phathom Pharmaceuticals, Inc.
• The shares are held with sole voting power over 2,330 shares and shared voting power over 300 shares.
• Prudential Financial, Inc. also holds sole dispositive power over 2,330 shares and shared dispositive power over 300 shares.
• The beneficial ownership is primarily attributed to its subsidiary, PGIM Quantitative Solutions LLC, which holds all 2,630 shares.
• Prudential Financial, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of a passive, non-material ownership stake, indicating no significant positive or negative implications for the issuer or the reporting person beyond routine compliance.

Positives

• The filing indicates a routine, passive investment by a major financial institution, suggesting normal portfolio management activities.
• The certification confirms that the investment is not for the purpose of influencing control, which can be a positive for existing management stability.

Negatives

• The disclosed ownership of 0.0% is not a material stake and therefore does not signal any significant new investment or confidence from Prudential Financial, Inc. in Phathom Pharmaceuticals, Inc.

Risks

• The document itself, being a Schedule 13G for a 0.0% stake, does not introduce new risks to Phathom Pharmaceuticals, Inc. It merely discloses a non-controlling, passive investment.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Phathom Pharmaceuticals, Inc.'s future outlook or operations. It is solely a disclosure of current beneficial ownership by a passive investor.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine regulatory disclosure by a large institutional investor, Prudential Financial, Inc., regarding a very minor, passive stake in a pharmaceutical company. It does not reflect any specific industry trends within the pharmaceutical sector or significant shifts in investment strategy by Prudential beyond standard portfolio adjustments.

Stakeholder Impact

• Shareholders: No material impact due to the very small, passive nature of the disclosed stake.
• Employees, Customers, Suppliers, Creditors: No direct or indirect impact from this beneficial ownership disclosure.

Next Steps

• Prudential Financial, Inc. will continue to file amendments to this Schedule 13G if there are material changes to its beneficial ownership of Phathom Pharmaceuticals, Inc.'s common stock.

Key Dates

Keywords

Phathom Pharmaceuticals, Prudential Financial, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor, SEC filing